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Antiangiogenic drugs are used clinically for treat-
ment of renal cell carcinoma (RCC) as a standard
first-line treatment. Nevertheless, these agents pri-
marily serve to stabilize disease, and resistance
eventually develops concomitant with progression.
Here, we implicate metabolic symbiosis between tu-
mor cells distal and proximal to remaining vessels as
a mechanism of resistance to antiangiogenic thera-
pies in patient-derived RCC orthoxenograft (PDX)
models and in clinical samples. This metabolic
patterning is regulated by the mTOR pathway, and
its inhibition effectively blocks metabolic symbiosis
in PDX models. Clinically, patients treated with anti-
angiogenics consistently present with histologic sig-
natures of metabolic symbiosis that are exacerbated
in resistant tumors. Furthermore, the mTOR pathway
is also associated in clinical samples, and its inhibi-
tion eliminates symbiotic patterning in patient sam-
ples. Overall, these data support a mechanism of
resistance to antiangiogenics involving metabolic
compartmentalization of tumor cells that can be in-
hibited by mTOR-targeted drugs.
INTRODUCTION
Angiogenesis is a crucial step in neoplastic progression that pro-
vides vascular support to the growing cancer mass while allow-
ing for tumor cell dissemination and metastasis. A number of
anti-angiogenic drugs are approved for clinical use in several
types of cancers (Folkman, 2007). Nevertheless, antiangiogenics
are typically not able to eliminate all tumor cells, giving raise to
tumor relapse. Therefore, clinical responses achieved with these
types of agents are moderate increases in survival, and are1134 Cell Reports 15, 1134–1143, May 10, 2016 ª 2016 The Authors
This is an open access article under the CC BY-NC-ND license (http://limited by therapeutic resistance that produces long-term failure
of these treatments (Kerbel and Folkman, 2002). In the case of
renal cell carcinoma (RCC), antiangiogenic drugs that block the
vascular endothelial growth factor (VEGF)/VEGF receptor
(VEGFR) pathway are now standard first-line treatment in meta-
static RCC and are used sequentially to prolong clinical benefit in
patients with recurrent disease (Rini, 2009). Nevertheless, resis-
tance to therapy ultimately emerges in most patients, and further
understanding of the underlying biology and potential therapeu-
tic targets are urgently needed in the clinic (Rini and Atkins,
2009).
Several different mechanisms of resistance to antiangiogenic
therapies have been described (Bergers and Hanahan, 2008).
Tumors may activate alternative pro-angiogenic signals that
produce revascularization and facilitate tumor regrowth (Casa-
novas et al., 2005). Less is known about alternative modes of
resistance to antiangiogenic therapies that do not involve revas-
cularization, where tumors adapt to hypoxic conditions for sur-
vival and tumor growth. Indeed, intratumor hypoxia induced by
antiangiogenic factors produces an accumulation of tumor
intrinsic and tumor microenvironmental modifications that
enhance survival, including metabolic adaptations to survive in
low oxygen and low nutrient conditions (De Bock et al., 2011).
Tumor cells have demanding metabolic requirements for their
high proliferative rate in an acidic and nutrient-depleted environ-
ment. This lack of proper oxygen and nutrient supply affects
tumor cell metabolism, and nutrient sensing pathways and trans-
porters are altered to support tumor cell survival (Schulze and
Harris, 2012). A particular form of adaptation to hypoxia is
metabolic symbiosis, where there is a coordinated compartmen-
talization of tumor cells and their use of glucose and lactate
(Sonveaux et al., 2008). In severely hypoxic regions tumor cells
import and metabolize glucose by anaerobic glycolysis with
upregulation of glucose transporter GLUT1 and lactate trans-
porter MCT4 (Ullah et al., 2006). On the other hand, in normoxic
regions, oxidative metabolism is permitted and these tumor cells
are typically lactate- and glutamine-avid, and express lactatecreativecommons.org/licenses/by-nc-nd/4.0/).
(legend on next page)
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transporters such as MCT1 (Sonveaux et al., 2008). This allows
for the mutual survival of these two tumor regions by compart-
mentalizing glycolysis and oxidative lactate metabolism at
different areas that exchange glucose and lactate for their meta-
bolic symbiosis.
Metabolic symbiosis has recently been described in several
mouse models of cancer in response to potent angiogenesis in-
hibitors (Pisarsky et al., 2016, and Allen et al., 2016, in this issue
ofCell Reports) but there has not been confirmatory assessment
in the clinical setting with human patient samples. Such valida-
tion will be necessary to establish this biological phenomenon
as a bona fide mode of adaptive resistance to anti-angiogenic
therapy, themechanism of whichmight suggest new therapeutic
targets aimed to circumvent it.
Here, we describe amechanism of resistance to antiangiogen-
ics in patient-derived orthoxenograft models of RCC that impli-
cates metabolic symbiosis between tumor cells that can be
blocked by mTOR inhibitors. Importantly, these results are sup-
ported by analysis of clinical biopsies from patients with treated
RCC, where antiangiogenics produce a metabolic symbiosis
pattern that is similarly suggested to be mediated by mTOR
pathway.
RESULTS
Resistance to Antiangiogenics in Patient-Derived Renal
Cell Carcinoma Orthoxenograft Models
To investigate tumor adaptation to anti-angiogenic treatments,
we developed a clinically relevant mouse model based on the
orthotopic implantation of primary biopsies of human clear-cell
RCC tumors, in which we evaluated response and acquired
resistance after VEGFR signaling inhibition with sunitinib. All
orthoxenograft tumors derived from primary biopsies initially re-
sponded to sunitinib antiangiogenic therapy, but eventually the
tumors rebounded, having adapted to treatment with sunitinib
(Figure 1A). Notably, each of these PDX models demonstrated
a distinctive efficacy of sunitinib at inhibiting tumor growth, but
this therapeutic phase was always followed by tumor regrowth
and resistance. Furthermore, these impairments of tumor growth
translated into extensions both of time-to-progression and life-
span (overall survival) in treated animals (Figure 1B).
To explore the mechanism underlying this resistance, we first
evaluated the histological features typically altered by antiangio-
genic treatment. In resistant tumors, microvessel density was
diminished, and both tumor hypoxia (Pimonidazole adducts
and GLUT1 membrane accumulation) and tumor necrosis were
consistently increased (Figures 1C–1E). Nevertheless, tumor
proliferation wasmaintained in the viable areas of these resistant
tumors, indicating that tumor cells circumvented the therapeutic
pressure to continue proliferating (Figure 1C). These results
coordinately describe a mechanism of resistance with reducedFigure 1. Sunitinib Treatment Effects in Patient-Derived RCC Orthoxen
(A) Tumor progression with sunitinib treatment in Ren28 and Ren96 RCC PDX tum
(C) Immunohistological staining of control and sunitinib-treated mice for CD31 (4
GLUT1 (203), and Ki67 (203).
(D and E) Quantification of microvessel density (D) and H&E and necrosis (E) (p
treatment group, four images each.
1136 Cell Reports 15, 1134–1143, May 10, 2016vascular density, without evident revascularization (Figure S1),
wherein tumor cells adapted to treatment-induced hypoxia and
were able to maintain proliferation and continuation of growth.
Antiangiogenic Resistance Is Associated with a
Metabolic Symbiosis Phenotype
RCC typically presents with von Hippel Lindau (VHL) mutations
that produce chronic hypoxic signaling cascades due to
HIF1a accumulation (Cancer Genome Atlas Research Network,
2013). Nevertheless, these tumors further respond to antiangio-
genic therapies with an enhanced hypoxia response transcrip-
tional program. Indeed, VHL-mutated RCC tumor cells further
elevate the transcriptional hypoxia response program when
cultured under hypoxia and partial nutrient depletion conditions
that mimic antiangiogenic therapy in full tumors (Figures S2A–
S2C). Furthermore, these cells increase glucose consumption
and lactate production under hypoxic conditions (Figure S2D).
Consistently, in our orthoxenograft models Ren28 and Ren96,
the expression of two hypoxia response transporters, glucose
transporter GLUT1 and the lactate exporter MCT4, were
increased by antiangiogenic treatment and accumulated distinc-
tively in peri-necrotic areas where the maximal hypoxia is pre-
sent (Figure 2A; Figure S3). Provocatively, the lactate importer
MCT1 was expressed in other non-overlapping regions of suniti-
nib-treated tumors, separate from the hypoxic and necrotic re-
gions (Figure 2A; Figure S3). This mutually exclusive localization
of MCT1 and MCT4 is reminiscent of metabolic symbiosis, a
form of coordinated compartmentalization of tumor cells and
their use of glucose and lactate (Sonveaux et al., 2008). Indeed,
sunitinib-resistant tumors showed a statistically significant in-
crease in expression area of both MCT1 and MCT4, but more
importantly, their pattern of expression changed from a low
co-expression in controls to a mutually exclusive compartmen-
talized symbiosis pattern (Figure 2B). Specifically, MCT4-posi-
tive regions were far from blood vessels (>40 mm in both
Ren28 and Ren96 models), but MCT1-positive regions were
close to vessels (mostly <30 mm in both models) (Figure S4).
Quantification of the incidence of this symbiosis pattern further
demonstrated the significant adaptive change of the compart-
mentalization in resistant tumors. While in control tumors the
metabolic symbiosis pattern was completely absent, the major-
ity of sunitinib-resistant tumors showed a clearly defined com-
partmentalized pattering (87%) (Figure 2C).
In a related paper in this issue ofCell Reports, Allen et al. (2016)
describe the association of mTOR signaling pathway activity in
analogous symbiotic clusters in a mouse model of pancreatic
neuroendocrine cancer (PanNET). Thus, we evaluated mTOR
pathway activity by means of phospho-S6 and phospho-S6K
in the resistant RCC tumors. Immunofluorescence staining
showed these mTOR activity markers accumulated specifically
in tumor regions close to vessels, co-localized with MCT1 andografts
ors starting at 1,000mm3, and (B) corresponding Kaplan-Meier survival curves.
03), pimonidazole adducts in green (PIMO) counterstained with DAPI (203),
ercentage of area) quantification graphed as box plots from four animals per
(legend on next page)
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were mutually exclusive with MCT4 areas (Figure 2D; data not
shown). These data clearly demonstrate that mTOR activity
was restricted to the MCT1-expressing normoxic compartment
in sunitinib-resistant tumors.
Blockade of Metabolic Symbiosis by Inhibition of mTOR
pathway
To determine the functional implication of mTOR signaling in the
metabolic symbiosis pattern, sunitinib-resistant tumors were
treated with a clinically approved mTOR inhibitor, everolimus.
The mTOR inhibitor demonstrated antitumor efficacy in this sec-
ond-line treatment, effectively blocking the adaptive resistance
to antiangiogenic therapy in Ren28, but not in the Ren96 PDX
model (Figure 3A). Similarly to the clinical setting, second-line
everolimus in patients has a variable efficacy, with a proportion
of patients not responding to this therapy (upfront refractory or
intrinsic resistant) (Motzer et al., 2014). To confirm mTOR
pathway inhibition in everolimus-treated PDX tumors, immuno-
fluorescent staining for the p-S6 and p-S6K markers demon-
strated that everolimus was indeed effectively inhibiting mTOR
activity in Ren28, but it was not active in Ren96 (Figure 3B).
This suggests that Ren96 PDXmodel could have a signalingmis-
regulation or mutation that renders it insensitive to everolimus
treatment. When the metabolic symbiosis phenotype was evalu-
ated in both tumor models, everolimus treatment produced a
substantial alteration in the expression area of the lactate
transporters MCT1 and MCT4 only in Ren28, with widespread
accumulation of MCT4, concomitant with reductions in MCT1-
positive regions (Figure 3B). Quantification of these regions
confirmed that everolimus treatment in Ren28 served to
unbalance the MCT1/MCT4 symbiotic equilibrium in favor of
MCT4-expressing areas, reducing MCT1-positive tumor areas
(Figure 3C). On the contrary, everolimus treatment did not
disrupt the sunitinib-resistance symbiotic pattern in the insensi-
tive Ren96 tumors (Figure 3D). This correlation suggests that
everolimus-induced disruption of the metabolic symbiosis
phenotype is fully dependent on everolimus efficacy in inhibiting
mTOR pathway. To pinpoint the mechanism of everolimus
decrease in MCT1-positive areas, an in vitro study was per-
formed with RCC cells. Everolimus treatment decreased tumor
cell viability by 53% (Figure S5), indicating that cell survival rather
than a transcriptional downregulation of MCT1 was occurring in
these cells. Thus, metabolic symbiosis abolishment by everoli-
mus is associated to decreased viability of this particular tumor
cell subpopulation.
Overall, the data implicate the mTOR pathway in this sunitinib
resistance mechanism by aiding the induction of the perivascu-
lar p-S6/MCT1-positive subcompartment. Furthermore, when
mTOR is effectively inhibited, sunitinib resistance is blocked,Figure 2. Metabolic Symbiosis of Sunitinib-Treated Tumors
(A) Immunohistofluorescence staining of Ren28 and Ren96 RCC PDX tumors show
with DAPI (203 magnifications).
(B) Quantification of expression of MCT1 and MCT4 in Ren28 and Ren96 as a pe
images each.
(C) Quantification ofmetabolic symbiosis pattern in Ren28- andRen96-treated tum
versus homogeneous, co-staining (no symbiosis pattern).
(D) Representative images of pS6, MCT1, and MCT4 immunohistofluorescence
1138 Cell Reports 15, 1134–1143, May 10, 2016evidently disrupting themetabolic symbiosis phenotype via elim-
ination of the pS6/MCT1-positive subpopulation in favor of the
GLUT1/MCT4-positive subpopulation.
Metabolic Symbiosis in RCC Patients after
Antiangiogenics
To further assess the metabolic symbiosis phenotype observed
in orthoxenograft models, we evaluated a series of 15 patients
with clear-cell RCC tumors who had been treated with antiangio-
genic therapy blocking the VEGF/VEGFR pathway (Figure S6A).
This series is unique because we obtained paired FFPE tumor
specimens before and after antiangiogenic treatment (either in
response or resistance), therefore allowing determination of
histopathological changes in each patient’s tumor pre- and
post-antiangiogenic treatment. Immunofluorescence staining
of lactate transporters in samples before and after antiangio-
genic treatment demonstrated that area with expression of
both MCT1 and MCT4 were significantly increased upon treat-
ment (Figure 4A, left; Figure S6B), suggestive of a metabolic
adaptation to treatment involving upregulation of lactate trans-
porters, similar to that observed in the tumor models. Impor-
tantly, localization of these transporters also occurred in a
compartmental, mutually exclusive pattern, with MCT1 ex-
pressed in well-oxygenated areas close to vessels, and MCT4
expressed in more hypoxic (GLUT1 in the membrane) areas
distal to tumor vessels (Figure S6C). Upon quantification, this
patterning was observed in 71% of the post-treatment samples
but completely absent in the pre-treatment samples, indicating
the strong adaptive nature of this event (Figure 4A, right). This
patterning strongly suggests a metabolic symbiosis phenotype
in patients, and is fully consistent with findings in orthoxenograft
tumor models.
Due to the differential clinical responses to treatment in each
of the 15 patients in study, they were grouped according to their
response or resistance to treatment (clinically stable disease, SD
versus progressive disease, PD) at the end of antiangiogenic
therapy, when the post- sample was obtained. Tumors from
responsive (n = 6) and resistant (n = 8) patients to antiangiogenic
treatment both expressed MCT1 and MCT4 after treatment (Fig-
ure 4B). Notably, however, only tumors from patients who pro-
gressed (having acquired a resistant phenotype) had a clearly
defined compartmentalization of MCT1 and MCT4, consistent
with metabolic symbiosis patterning (Figure 4B). Quantification
revealed that metabolic symbiosis patterning was observed in
100% of the post-samples from resistant tumors, whereas in pa-
tients still in the response phase (SD) the incidence was 33%
(Figure 4C). Thus, this singular series of treated and biopsied
patients supports the proposition that antiangiogenic resistance
involves the formation of two mutually exclusive tumor celling representative images ofMCT1, GLUT1, MCT4, and CD31, counterstained
rcentage of positive area per field, from four animals per treatment group, four
ors as presence ofMCT1/MCT4mutually exclusive pattern (symbiosis pattern)
staining in RCC PDX tumors.
(legend on next page)
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compartments, a perivascular region andMCT1 expression, and
another peri-necrotic region expressing MCT4 and a GLUT1/
hypoxia response.
Motivated by the orthoxenograft results, mTOR pathway
involvement was also evaluated. The phospho-S6mTOR activity
marker was also compartmentalized in post-treatment samples
and, similar to orthoxenograft results, it was expressed in a
mutually exclusive pattern with MCT4 lactate exporter (Fig-
ure 4D). Whereas our series of pre- and post-samples were
from antiangiogenic-treated patients, we obtained samples
from one patient with RCC that was effectively treated with
mTOR inhibitor (second line) just after antiangiogenics (first
line). In this patient (patient no. 12), only MCT4 expression was
detected after progression to mTOR inhibitor treatment, and
there was no compartmentalization patterning (Figure 4E).
Although these data are from one individual, the results are fully
consistent with animal models wheremTOR inhibition selectively
eliminated the MCT1 compartment, leaving the MCT4-positive
tumor compartment comparatively intact.
Collectively, this singular set of sunitinib-treated and succes-
sively biopsied patients supports the hypothesis that antiangio-
genic treatment induces a metabolic symbiosis patterning in
RCC that is further exacerbated in progressive (resistant)
tumors. Furthermore, the mTOR pathway is also implicated
as involved in inducing and maintaining the MCT1-positive
compartment in the metabolic symbiosis.
DISCUSSION
Our study, together with Pisarsky et al. (2016) and Allen et al.
(2016), establish in mouse models of three different tumor types
a new mode of resistance to antiangiogenic therapies, involving
metabolic symbiosis among differential subcompartments of tu-
mor cells. Indeed, metabolic symbiosis has been described as a
mode of adaptation to tumor hypoxia (Sonveaux et al., 2008), but
here we coordinately describe this phenomenon as an active
mechanism of resistance to potent antiangiogenic therapies in
three different tumor types (pancreatic neuroendocrine tumor,
breast cancer, and RCC).
Several different modes of resistance to antiangiogenic thera-
pies have been described, including the induction of revascular-
ization and reoxygenation of tumors by different mechanisms
(Bergers and Hanahan, 2008; Casanovas et al., 2005). Neverthe-
less, here we describe a mechanism of resistance in the
context of continuing suppression of tumor neo-vascularization,
whereby tumor cells adapt to treatment-induced hypoxia to
enable continuing proliferation and growth. This adaptation in-
volves a functional compartmentalization of energy metabolismFigure 3. Everolimus Effects as a Second-Line Treatment in Patient-D
(A) Tumor progression of treatment with sunitinib or sunitinib followed by everol
responding Kaplan-Meier survival curves.
(B) Representative images of pS6 and S6kinase immunohistochemistry staini
counterstained with DAPI (203 magnifications).
(C) Quantification of expression MCT1 and MCT4 in Ren28 and Ren96 in the diffe
treatment group, four images each.
(D) Quantification ofmetabolic symbiosis pattern in Ren28- andRen96-treated tum
versus homogeneous, co-staining (no symbiosis pattern).
1140 Cell Reports 15, 1134–1143, May 10, 2016previously described as metabolic symbiosis by Dewhirst and
colleagues (Sonveaux et al., 2008). This is a form of coordinated
compartmentalization of tumor cells and their differential use
of glucose and lactate that produces a mutually exclusive
patterning of MCT1-expressing cells andMCT4. This is function-
ally relevant as the hypoxic and peri-necrotic region upregulate
hypoxia-response genes (GLUT1, PDK1, GAPDH, etc.) to acti-
vate anaerobic glycolysis and export accumulated lactate to
the extracellular space via MCT4 lactate/H+ symporter. On the
other hand, the perivascular compartment is better oxygenated
and permits oxidative phosphorylation, for which it imports
accumulated lactate to be further metabolized aerobically to
obtain energy (Sonveaux et al., 2008).
With these data, a more clinically relevant question emerges:
Is there a way to block this metabolic symbiosis phenotype to
therapeutically attack these antiangiogenic-resistant tumors?
Consistent with Allen et al. (2016), we have produced evidence
that the mTOR signaling pathway has an important role in this
symbiotic compartmentalization, and it can be therapeutically
targeted. mTOR activity markers reveal that this pathway is
restricted to better oxygenated MCT1-positive areas, close to
vessels, consistent with the report by Allen et al. (2016) Thus,
therapeutic inhibition of this pathway with mTOR (mTORC1) in-
hibitors such as everolimus and rapamycin disrupts the symbi-
otic pattern and unbalances this equilibrium by eliminating the
MCT1-positive areas, accumulating glycolyticMCT4-positive tu-
mor cells, and increasing necrosis by oxygen and nutrient deple-
tion. The result is anti-tumor therapeutic benefit, and suggests
everolimus as a useful second-line treatment after antiangio-
genic therapy. Indeed, this is a typical sequence of treatment
in metastatic RCC, where the standard first-line treatment is
with antiangiogenic drugs and, upon resistance (disease pro-
gression), follow-up treatment with everolimus (RECORD trials)
(Motzer et al., 2014).
An important shortcoming in the concurrent metabolic symbi-
osis studies is that they are restricted to animal model studies,
such that it remained to be determined whether this adaptive
resistance mechanism was operative in human cancer treated
with anti-angiogenic drugs. Here, we present the first validation
of metabolic symbiosis in a series of 15 patients with clear cell
RCC tumors treated with antiangiogenic therapies. By obtaining
a set of uniquely paired FFPE tumor specimens before and after
antiangiogenic treatment, we detected compartmentalization
upon treatment, with mutually exclusive patterns of perivascular
MCT1 and peri-necrotic/hypoxic MCT4 areas, strongly sugges-
tive of a metabolic symbiosis phenotype in patients. Further-
more, this patterning was most prominent in tumors that had
adapted and progressed on therapy, consistent with metabolicerived RCC Orthoxenografts
imus in Ren28 and Ren96 RCC PDX tumors starting at 1,000 mm3, and Cor-
ng, and pS6, MCT4, MCT1, and MCT4 immunohistofluorescence staining,
rent treatments as percentage of positive area per field, from four animals per
ors as presence ofMCT1/MCT4mutually exclusive pattern (symbiosis pattern)
(legend on next page)
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symbiosis patterning occurring in and contributing to the
resumed progression in resistant tumors.
Moreover, we have implicated involvement of the mTOR
pathway in the adaptive resistance via metabolic compartmen-
talization in patient tumors, where the perivascular subcompart-
ment shows mTOR signaling activity and MCT1 expression.
Furthermore, mTOR inhibition in a patient further substantiates
the promising value of targeting mTOR to block metabolic sym-
biosis and overall resistance to antiangiogenics in patients.
In summary, our study describes a mode of resistance to anti-
angiogenic therapies in orthotopic RCC PDXmouse models and
in human patients, involving metabolic symbiosis compartmen-
talization of tumors. This resistance mechanism can be blocked
therapeutically with mTOR inhibitors that disrupt the symbiosis
by eliminating one of the symbiotic compartments, which may
be important for the benefits of this drug when used second
line after resistance to angiogenesis inhibitors.
EXPERIMENTAL PROCEDURES
Patient-Derived Orthoxenograft Models from RCC Human Biopsies
Fresh surgical specimens of RCC were obtained from the Bellvitge and Vall
d’Hebron Hospitals under local ethics committee’s approved protocols
(CEIC approvals ref. PR322/11 and PR[AG]240/2013). Their surgical implanta-
tion was done orthotopically in the kidney (original neoplastic organ) in male
athymic nude mice (Harlan Laboratories). All animal experiments were devel-
oped according to our Institute’s Animal Research Committee acceptance,
and following Spanish laws and European directives on ethical usage of
rodents for animal research (approval DARP-#4899).
Treatment Schedule
Once the tumor was palpable (1,000 mm3 of volume), five to six animals were
randomized to receive treatments. Sunitinib (LC Labs) was prepared and
dosed at 40 mg/kg/day orally as described (Pa`ez-Ribes et al., 2009). Everoli-
mus (LC Labs) was prepared and dosed at 10 mg/kg/day orally. At the end of
treatment, mice were killed, and the tumor tissue was weighed and processed
for histology.
Immunohistology and Quantifications
Frozen or FFPE tumor sections were stained with H&E and immunohistology
techniques as described (Pa`ez-Ribes et al., 2009). Primary antibodies were
rabbit anti-GLUT1 (Abcam, ab652), mouse anti-CD31 (Abcam, ab28364), rab-
bit anti-Ki67 (Thermo Sci., RM9106 S-1), anti-PS6 (Cell Signaling, 4857), anti-
pS6K (Abcam, ab32359), rabbit anti-GLUT1 (Abcam ab652), rabbit anti-PS6
(Cell Signaling, 4857), rabbit anti-MCT1 (H-70) (SCB, SC-50324), rabbit anti-
MCT4 (H-90) (SCB, SC-50329), and anti-pimonidazole (NPI, 4.3.11.3). Double
or triple stainings with same-species antibodies were done with tyramide fol-
lowed by fixation as described.
To quantify CD31, Ki67, and GLUT1 staining, four hotspot fields in viable tis-
sue zones at 4003magnification were captured for each tumor. MCT1/MCT4
area density quantification was done with positive-pixel-area/total-image-Figure 4. Metabolic Symbiosis after Antiangiogenic Treatment in RCC
(A) Left, Quantification of expression MCT1 and MCT4 in RCC in basal levels (p
treatment samples), represented as percentage of positive area per field. Right, q
above.
(B) Representative images of MCT1, MCT4, and CD31 immunohistofluorescence
(C) Quantification of metabolic symbiosis pattern in RCC according to clinical resp
samples.
(D) Representative images of GLUT1, MCT1, pS6, and MCT4 immunohistofluore
(E) Schematic diagram of treatment schedule for a patient treatment sequence a
CD31 before and after antiangiogenic-positive mTOR inhibition treatments.
1142 Cell Reports 15, 1134–1143, May 10, 2016pixel-area, using ImageJ software. Hypoxia was detected with pimonidazole
(intraperitoneal 60 mg/kg) 1 hr before heart perfusion, and immunodetected
with histological techniques as described above.
Patient Series and Clinical Data
The series of pre- and post-samples from patients with RCC was gathered
prospectively and retrospectively between 2007 and 2014 under clinical
ethics committee approval (IDIBELL CEIC approval ref. PR322/11, and
VHIO CEIC approval ref. PR[AG]240/2013), and acceptance by the Spanish
Government (AEMPS). A total of 15 clear-cell RCC samples from previously
untreated patients were selected, and pre-treatment and post-treatment
biopsies and/or surgical specimens were collected (including four post-treat-
ment autopsy samples). These patients were treated with antiangiogenic
therapy (mostly sunitinib and a few bevacizumab at standard dose) and
the response was evaluated by RECIST guidelines (tumor progression PD,
resistance; or tumor response SD, in efficacy) at the end of antiangiogenic
treatment.
Statistical Analysis
Statistical comparisons between treatment groups were done using the
Mann-Whitney U test (2-tailed), performed in GraphPad Prism. Differences
were considered statistically significant at p < 0.05. Statistics coding:
****p < 0.0001; ***p < 0.001; **p < 0.01, and *p < 0.05.
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